国金证券认为，随着年底各类国家和地方集采、谈判等陆续落地出清，医药板块整体有望迎来估值修复机会。湘财证券则指出，四季度板块催化事件密集，创新药国谈及仿制药国采陆续启动，建议关注相关品种纳入医保及市占率提升投资机会。Some pharmaceutical stocks rose in the morning session. As of the time of writing, Remegen (09995) was up 8.73% at HK$15.7; Sinolink Pharmaceutical-B (02171) was up 6.47% at HK$15.7; YunDingXinYao-B (01952) was up 2.11% at HK$31.5; Fosun Pharma (02196) was up 3.7% at HK$15.12.
According to the Zhongtong Finance and Economics APP, some pharmaceutical stocks rose in the morning session. As of the time of writing, Remegen (09995) was up 8.73% at HK$15.7; Sinolink Pharmaceutical-B (02171) was up 6.47% at HK$15.7; YunDingXinYao-B (01952) was up 2.11% at HK$31.5; Fosun Pharma (02196) was up 3.7% at HK$15.12.
On October 25th, the National Chinese Patent Medicine Joint Procurement Office released the third batch of the national group procurement draft for Chinese patent medicine: led by Hubei, involving 20 product groups with a total of 95 products. The practice of the previous two batches will continue, combining different generic drugs with similar indications or main functions for centralized quantity-based procurement. The medical insurance negotiation for the 2024 directory started in Beijing on October 27th, with 162 drugs expected to complete on-site negotiations and bidding within 4 days. The results are expected to be announced in November 2024 and implemented on January 1, 2025.
Sinolink Securities believes that with the gradual implementation and clearance of various national and local group procurement and negotiations by the end of the year, the pharmaceutical sector as a whole is expected to welcome a valuation recovery opportunity. Xiangcai Securities also pointed out that the fourth-quarter catalytic events in the sector are intensive, with discussions on innovative drug national negotiations and generic drug national procurement gradually commencing. It is recommended to focus on relevant varieties included in medical insurance and opportunities for market share enhancement.
